» Articles » PMID: 31092904

Tertiary Lymphoid Structures in the Era of Cancer Immunotherapy

Overview
Journal Nat Rev Cancer
Specialty Oncology
Date 2019 May 17
PMID 31092904
Citations 739
Authors
Affiliations
Soon will be listed here.
Abstract

Tertiary lymphoid structures (TLSs) are ectopic lymphoid organs that develop in non-lymphoid tissues at sites of chronic inflammation including tumours. Key common characteristics between secondary lymphoid organogenesis and TLS neogenesis have been identified. TLSs exist under different maturation states in tumours, culminating in germinal centre formation. The mechanisms that underlie the role of TLSs in the adaptive antitumour immune response are being deciphered. The description of the correlation between TLS presence and clinical benefit in patients with cancer, suggesting that TLSs could be a prognostic and predictive factor, has drawn strong interest into investigating the role of TLSs in tumours. A current major challenge is to exploit TLSs to promote lymphocyte infiltration, activation by tumour antigens and differentiation to increase the antitumour immune response. Several approaches are being developed using chemokines, cytokines, antibodies, antigen-presenting cells or synthetic scaffolds to induce TLS formation. Strategies aiming to induce TLS neogenesis in immune-low tumours and in immune-high tumours, in this case, in combination with therapeutic agents dampening the inflammatory environment and/or with immune checkpoint inhibitors, represent promising avenues for cancer treatment.

Citing Articles

PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial.

Wang Y, Lu J, Chong X, Wang C, Chen X, Peng Z Signal Transduct Target Ther. 2025; 10(1):100.

PMID: 40082418 PMC: 11906745. DOI: 10.1038/s41392-025-02193-z.


Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma.

De Domenico P, Gagliardi F, Roncelli F, Snider S, Mortini P J Neurooncol. 2025; .

PMID: 40080248 DOI: 10.1007/s11060-025-04989-z.


Immune Cell Interplay in the Fight Against GBM.

Vallieri N, Datsi A Cancers (Basel). 2025; 17(5).

PMID: 40075663 PMC: 11899300. DOI: 10.3390/cancers17050817.


Quantifying and interpreting biologically meaningful spatial signatures within tumor microenvironments.

Jing S, Wang H, Lin P, Yuan J, Tang Z, Li H NPJ Precis Oncol. 2025; 9(1):68.

PMID: 40069556 PMC: 11897387. DOI: 10.1038/s41698-025-00857-1.


Prognostic implications and characterization of tumor-associated tertiary lymphoid structures genes in pancreatic cancer.

Zhang E, Ma Y, Liu Z, Zhang J, Liu W, Chen Y J Transl Med. 2025; 23(1):301.

PMID: 40065365 PMC: 11892293. DOI: 10.1186/s12967-025-06152-8.


References
1.
Vogelstein B, Fearon E, Hamilton S, Kern S, Preisinger A, Leppert M . Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319(9):525-32. DOI: 10.1056/NEJM198809013190901. View

2.
Schumacher T, Schreiber R . Neoantigens in cancer immunotherapy. Science. 2015; 348(6230):69-74. DOI: 10.1126/science.aaa4971. View

3.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C . Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-4. DOI: 10.1126/science.1129139. View

4.
Fridman W, Zitvogel L, Sautes-Fridman C, Kroemer G . The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017; 14(12):717-734. DOI: 10.1038/nrclinonc.2017.101. View

5.
Mellman I, Coukos G, Dranoff G . Cancer immunotherapy comes of age. Nature. 2011; 480(7378):480-9. PMC: 3967235. DOI: 10.1038/nature10673. View